← Back to Stock Screener← Stock Screener

ZYBERNO

Stock Report

Updated Sep 1, 2026

EVOFEM BIOSCIENCES, INC. (EVFM)

Healthcare • OTC

$0.01

Professional Investment Analysis

ZYBERNO SCORE →

Is it a great business? Is it getting better?

15.0/100

POOR BUSINESS

EVOFEM BIOSCIENCES, INC. (EVFM) scores 15/100 — concerning metrics indicating significant structural or financial risks.

📊 How is the Zyberno Score calculated? +

The Zyberno Score answers one question: "Is this a quality business worth owning?" It's a 0-100 investment grade that evaluates business fundamentals across four critical dimensions, based on principles from Warren Buffett, Benjamin Graham, Peter Lynch, and Charlie Munger.

The 4 Core Categories (25 points each):

1. PROFITABILITY (25 pts)

Metrics: ROE, ROIC, Net Margin, Operating Margin
Thresholds: ROE >20% excellent • ROIC >20% excellent • Net Margin >20% excellent • Operating Margin >25% excellent

2. FINANCIAL STRENGTH (25 pts)

Metrics: Debt-to-Equity, Current Ratio, Interest Coverage, Altman Z-Score
Thresholds: D/E <0.3 excellent • Current Ratio >2.5 excellent • Interest Coverage >10x excellent • Altman Z >3.0 safe

3. CASH FLOW QUALITY (25 pts)

Metrics: Free Cash Flow, OCF vs Net Income, FCF Margin
Thresholds: Positive & growing FCF excellent • OCF/NI >1.2x excellent (cash earnings exceed accounting)

4. GROWTH & CONSISTENCY (25 pts)

Metrics: Revenue Growth, Net Income Growth, FCF Growth, Piotroski F-Score
Thresholds: Growth via log-linear regression • Piotroski 8-9 excellent, 6-7 good

Score Interpretation:

75-100

GREAT BUSINESS

65-74

GOOD BUSINESS

50-64

AVERAGE BUSINESS

30-49

WEAK BUSINESS

0-29

POOR BUSINESS

→ View full EVFM quality analysis & detailed breakdown

VALUATION SIGNAL

N/A (Requires more data)

Requires fair value calculation and current price data

💰 How is Margin of Safety calculated? +

Margin of Safety measures how much discount or premium you're paying relative to a stock's intrinsic value. It's Benjamin Graham's core principle: the larger the margin, the lower your downside risk.

Formula: (Intrinsic Value − Current Price) ÷ Intrinsic Value × 100%

How We Calculate Intrinsic Value (DCF Method):

Step 1: Calculate current Owner Earnings (OCF − Maintenance CapEx)

Step 2: Calculate company-specific growth rate using log-linear regression on 16 quarters of Owner Earnings

Step 3: Project 10 years forward using the calculated growth rate

Step 4: Discount each year's cash flow to present value using 10% discount rate

Step 5: Calculate terminal value using 3% perpetual growth rate

Step 6: Sum all discounted cash flows = Intrinsic Value

What The Percentages Mean:

+50% or more

EXCELLENT — Very undervalued

+25% to +50%

GOOD — Attractive discount

0% to +25%

FAIR — Reasonable value

0% to -25%

CAUTION — Slight premium

-25% or worse

POOR — Overvalued

"Price is what you pay, value is what you get." — Warren Buffett

→ View full EVFM valuation analysis · → View full EVFM Brina Gap analysis

📈 How is Brina Gap calculated? +

Brina Gap measures the difference between the growth a business can fundamentally sustain and the growth the market is already pricing in.

Formula: Fundamental Growth Rate − Market-Implied Growth Rate

The Two Components:

Fundamental Growth Rate = ROIC × Reinvestment Rate

What the business can sustainably grow at based on how much it reinvests and what return it earns on that capital. Grounded in historical financials.

Market-Implied Growth Rate = Reverse DCF

The growth rate the current Enterprise Value implicitly assumes. Calculated by back-solving a 10-year DCF model (10% WACC, 3% terminal growth) until the present value of projected cash flows equals EV.

What The Gap Means:

Gap > +5% Market Underestimates — potential upside

+2% to +5% Slight Underestimate

-2% to +2% Fairly Priced — market consensus matches fundamentals

-5% to -2% Slight Overestimate

Gap < -5% Market Overestimates — price embeds optimism fundamentals don't support

A positive gap (market underestimates) combined with a positive Margin of Safety is the strongest combined signal — the business is both cheap historically and forward economics are stronger than the price suggests.

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)

Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)

Operating Margin (Operational Efficiency):CRITICAL (-15.3%)

Return on Capital (Capital Efficiency):CRITICAL (-34.3%)

📊 Valuation Trilogy

Three interconnected metrics for complete valuation analysis

Click any metric for full methodology and detailed analysis

Zyberno's Verdict

EVOFEM BIOSCIENCES, INC. (EVFM) stock report — Zyberno Score 15/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, EVFM generated -$268.00K in Owner Earnings. Capital was deployed as follows: $5.00K invested in capital expenditures. Reinvestment rate: -2.9%.

DIVISION I: EXECUTIVE SUMMARY

A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.01

Market Cap:$1.13M

Valuation Multiples (2)

P/S Ratio:0.06x

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$10.93M

Price Action & Momentum (3)

12-1 Momentum:

-25.0% (22th pctile)

📈 Click to view full EVFM Momentum analysis →

Momentum Percentile:22 / 100

% of 52-Week High:41.3%

B. Profitability Assessment

Return Metrics (4)

ROA:-124.6%

Roic:

-34.3%

📊 Click to view full EVFM ROIC analysis →

Reinvestment Rate:-2.9%

Fundamental Growth Rate (g):1.0%

Margin Analysis (3)

Operating Margin Ttm:-15.3%

Net Margin Ttm:-84.7%

Ebitda Margin:-11.5%

TTM Performance (3)

Gross Margin Ttm:75.5%

Operating Margin Ttm:-15.3%

Net Margin Ttm:-84.7%

Yield Metrics (2)

Earnings Yield:-$1.33K

Dividend Yield:0.0%

C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

Earnings Surprise (SUE):

+0.01

📊 Click to view full EVFM Earnings Surprise analysis →

EPS Surprise vs Expected:12.9%

Latest Earnings Filed:2026-08-14

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-14.9%

Earnings Growth (Linear) (1)

Net Income Growth Rate (Linear):-50.0%

Cash Flow Growth (Linear) (2)

Free Cash Flow Growth Rate (Linear):100.0%

Operating Cash Flow Growth Rate (Linear):73.1%

D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.07x

Quick Ratio:0.04x

Cash Ratio:0.02x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:1.40x

Times Interest Earned:1.40

Capital Structure (4)

Working Capital:-82,533,000.00

Cash And Cash Equivalents:1,491,000.00

Long Term Debt:$118.00K

Net Debt:$9.80M

DIVISION II: FINANCIAL STATEMENTS ANALYSIS

A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $18.05M

Linear Growth: -14.9%

📊 Click to view full EVFM Revenue analysis & methodology →

Cost Of Revenue Ttm:$4.42M

Profitability Breakdown (2)

Gross profit TTM: $13.63M

Linear Growth: 5.4%

📊 Click to view full EVFM Gross Profit analysis & methodology →

-$2.76M

Bottom Line Performance (3)

Net income TTM: -$15.28M

Linear Growth: -50.0%

📊 Click to view full EVFM Net Income analysis & methodology →

Income Before Tax:-$15.29M

Ebitda Ttm:-2,077,000.00

Operating Expenses (5)

Operating Expenses:20,807,000.00

R And D Expense:1,845,000.00

Sga Expense:7,385,000.00

Income Tax Expense:$6.00K

Interest Expense:2,403,000.00

Expense Ratios (3)

R And D To Revenue Percentage:70.1%

Sga To Revenue Percentage:280.5%

Ebitda Margin:-11.5%

B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$7.52M

Current Assets:$6.08M

Ppe Net:412,000.00

Goodwill:0.00

Intangible Assets:$869.00K

Liability Structure (4)

Total Liabilities:95,038,000.00

Current Liabilities:88,615,000.00

Long Term Debt:$118.00K

Short Term Debt:$11.17M

Equity & Capital (3)

Equity:-$87.52M

Retained Earnings:-$914.02M

Common Stock:3,000,000,000.00

Working Capital Items (3)

Accounts Receivable:2,497,000.00

Inventory:2,155,000.00

Accounts Payable:12,150,000.00

Special Items (2)

Contract Liabilities:377,000.00

Stock Based Compensation:15,000.00

C. Cash Flow Analysis

Operating Activities (2)

Operating cash flow TTM: -$251.00K

Linear Growth: 73.1%

Free cash flow TTM: -$256.00K

Linear Growth: 100.0%

📊 Click to view full EVFM Free Cash Flow analysis & methodology →

Investment Activities (2)

Investing Cash Flow:-$2.00K

Capital Expenditures Ttm:5,000.00

Financing Activities (3)

Financing Cash Flow:-$498.00K

Dividends Paid Ttm:0.00

Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00

Long Term Debt Issuance:$650.00

Long Term Debt Repayments:$100.00K

Non-Cash Items (1)

Depreciation Amortization Ttm:685,000.00

DIVISION III: OPERATIONAL METRICS

A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.11

-$0.10

Earnings Per Share Ttm:-$0.11

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.13

Operating Cash Flow Per Share:-$0.01

Book Value & Capital (2)

Book Value Per Share:-$0.64

Cash Per Share:0.01

Dividend Policy (1)

Dividend Payout Ratio:-999.00x

B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:1.47x

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:7.23x

Days Sales Outstanding Ttm:50.51

Inventory Management (2)

Inventory Turnover Ttm:2.05x

Days Inventory Outstanding Ttm:178.04

Payables & Cash Cycle (2)

Days Payable Outstanding:1,003.79

Cash Conversion Cycle:-775.25

C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00

Quality Score:45.00

Market Metrics (2)

Beta:0.00x

Volatility Category:unknown

DIVISION IV: INVESTMENT ANALYSIS

A. Value Investment Framework

Owner Earnings Analysis (1)

-$268.00K

Damodaran Growth Analysis (2)

Reinvestment Rate:-2.9%

Fundamental Growth Rate (g):1.0%

B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (2)

Revenue Growth Rate (Linear):-14.9%

Net Income Growth Rate (Linear):-50.0%

Cash Flow Growth Rates (2)

Free Cash Flow Growth Rate (Linear):100.0%

Operating Cash Flow Growth Rate (Linear):73.1%

Other Growth Rates (1)

Gross Profit Growth Rate (Linear):5.4%

C. Company Profile & Context

Corporate Information (6)

Symbol:EVFM

Company Name:EVOFEM BIOSCIENCES, INC.

Sector:Healthcare

Industry:Pharmaceuticals

Exchange:OTC

Country:United States

Market Classification (3)

Market Cap Category:N/A

Price Category:penny

Volume Category:N/A

Share Structure (3)

Shares Outstanding:137.34M

Shares Outstanding Basic:137.34M

Shares Outstanding Diluted:137.34M

Data Processing Info (3)

Processing Version:v3.0

Last Updated:2026-09-01 22:20:08 UTC

Data Timestamp:2026-08-22T16:56:55.933339